Which YC batch was Altay Therapeutics in?

Altay Therapeutics was in Y Combinator's Winter 2020 batch (W20).

Is Altay Therapeutics still active?

Y Combinator lists Altay Therapeutics as active.

Where is Altay Therapeutics based?

Altay Therapeutics lists San Francisco, CA, USA; South San Francisco, CA, USA as its location on YC's directory.

Altay Therapeutics: YC W20 company, active

Founders

Not read from YC yet; the weekly run fills these in.

Same space

Competitors

Closest in what they build, same category.

Lavo Life SciencesW23AI for drug formulationShared: ai-powered drug discovery, biotech, drug discoveryInactive
Arpeggio BioS19Arpeggio Bio develops drugs targeting transcription factors using AI…Shared: biotech, drug discoveryActive

Adjacent

Overlapping tags, a different niche.

Origami Therapeutics, Inc.W22Oral drugs to halt neurodegenerationShared: biotech, therapeutics, drug discoveryActive
Eris BiotechW24Our drugs engage the immune system to fight tumorsShared: biotech, therapeutics, drug discoveryActive
AlixiaW22Targeting the Tumor Ecosystem to address cancer drug resistance.Shared: biotech, therapeutics, drug discoveryActive
Harmonic DiscoveryS21Multi-targeted therapeutics to treat complex diseasesShared: ai-powered drug discovery, biotech, drug discoveryActive
ParcelBioW24Elevated mRNA for transformative medicines.Shared: biotech, therapeutics, drug discoveryActive

Also from W20 in AI

Batchmates in Winter 2020.

About Altay Therapeutics

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.

San Francisco, CA, USA; South San Francisco, CA, USA